Medicinova Inc (MNOV) 5.98 $MNOV
MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
GlobeNewswire - Wed May 25, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that two abstracts detailing novel findings from further analysis of the completed clinical trial of MN-166 (ibudilast) in alcohol dependence have been accepted for presentation at the 39 Annual Scientific Meeting of the Research Society on Alcoholism to be held June 25-29, 2016 at the Hyatt Regency New Orleans in New Orleans, LA.
MNOV: 5.98 (+0.07)
MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada
GlobeNewswire - Wed Apr 20, 5:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, will present interim data today from MediciNova's ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the American Academy of Neurology (AAN) 68th Annual Meeting at the Vancouver Convention Centre in Vancouver, BC, Canada. The interim analysis, which was performed by an independent statistician consultant, includes a total of 25 subjects without non-invasive ventilator support who completed the 6-month double-blind treatment period with complete spirometry (respiratory function test) data.
MNOV: 5.98 (+0.07)
MediciNova, Inc. (NASDAQ: MNOV) - Analyst Coverage Initiated; Report by Broad Street
ACCESSWIRE - Mon Apr 04, 7:02AM CDT
LA JOLLA, CA / ACCESSWIRE / April 4, 2016 / MediciNova, Inc. (NASDAQ: MNOV) a biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market, recently announced that the medical journal Drug and Alcohol Dependence has published a new article regarding positive findings from a completed Phase 1b clinical trial of MN-166 (ibudilast) in methamphetamine dependence. The article, which was written by Matthew J. Worley, Keith G. Heinzerling, and colleagues at the University of California, Los Angeles (UCLA), reports that MN-166 (ibudilast) was shown to significantly reduce the subjective effects of methamphetamine in subjects diagnosed with methamphetamine dependence. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased that the detailed results of the first clinical trial evaluating MN-166 in methamphetamine-dependent subjects have been published. Based on the reported positive findings from this study, we continue to work in collaboration with researchers at UCLA on a much larger ongoing Phase 2 clinical study to evaluate MN-166 in methamphetamine-dependent subjects."
MNOV: 5.98 (+0.07)
MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
GlobeNewswire - Wed Mar 30, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the medical journal Drug and Alcohol Dependence has published a new article regarding positive findings from a completed Phase 1b clinical trial of MN-166 (ibudilast) in methamphetamine dependence. The article, which was written by Matthew J. Worley, Keith G. Heinzerling, and colleagues at the University of California, Los Angeles (UCLA), reports that MN-166 (ibudilast) was shown to significantly reduce the subjective effects of methamphetamine in subjects diagnosed with methamphetamine dependence.
MNOV: 5.98 (+0.07)
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China
GlobeNewswire - Sun Mar 27, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a notice of allowance from the Chinese Patent Office for a new patent which covers MN-001 (tipelukast).
MNOV: 5.98 (+0.07)
MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas
GlobeNewswire - Sun Feb 07, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that principal investigator Sandra Comer, Ph.D., Professor, Department of Psychiatry, Columbia University and New York State Psychiatric Institute (NYSPI), will present results of the completed Phase 2 trial which evaluated MN-166 (ibudilast) in patients with opioid dependence. Dr. Comer's presentation will be held during the symposium titled, "Glial and Neuroinflammatory Modulators for Attenuating Some Abuse-Related Effects of Drugs," at the Behavior, Biology and Chemistry Annual Meeting and Symposium.
MNOV: 5.98 (+0.07)
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis
GlobeNewswire - Wed Jan 27, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced NASH (nonalcoholic steatohepatitis) with fibrosis.
MNOV: 5.98 (+0.07)
FDA Grants Rare Pediatric Disease Designation to MediciNova's MN-166 (ibudilast) for the Treatment of Krabbe Disease
GlobeNewswire - Mon Jan 18, 5:16PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to MN-166 (ibudilast) for treatment of Type 1 - Early Infantile Krabbe disease. Under the FDA's rare pediatric disease priority review voucher program, the sponsor may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug application. The FDA has previously granted orphan drug designation to MN-166 (ibudilast) for treatment of Krabbe disease.
MNOV: 5.98 (+0.07)
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in Europe
GlobeNewswire - Wed Jan 13, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced receipt from the European Patent Office of a notice of intent to allow patent for MN-029 (denibulin) di-hydrochloride.
MNOV: 5.98 (+0.07)
FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis
GlobeNewswire - Wed Dec 16, 5:00AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-166 (ibudilast) for the treatment of patients with amyotrophic lateral sclerosis (ALS). Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA's Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.
MNOV: 5.98 (+0.07)
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in China
GlobeNewswire - Mon Dec 14, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a notice of allowance for a new patent from the Chinese Patent Office which covers MN-029 (denibulin) di-hydrochloride.
MNOV: 5.98 (+0.07)
MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL
GlobeNewswire - Sun Dec 13, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, today presented interim data from MediciNova's ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 26th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) in Orlando, FL. The interim analysis includes a total of 36 subjects, and 33 of those subjects completed 6 months of treatment on study drug (MN-166 or placebo in a 2:1 ratio).
MNOV: 5.98 (+0.07)
MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
GlobeNewswire - Wed Dec 09, 4:30PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Daniel Roche today presented results based on the completed study which evaluated the safety and efficacy of MN-166 (ibudilast) in alcohol use disorder (Dr. Lara Ray, UCLA, Principal Investigator) at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting.
MNOV: 5.98 (+0.07)
MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th Annual California ALS Pac10 and Research Network Meeting at UCSD, La Jolla, Californiaã??
GlobeNewswire - Sun Dec 06, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that Dr. Yuichi Iwaki, President and CEO, has accepted an invitation to make a presentation regarding the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 6th Annual California ALS Pac10 and Research Network Meeting which will be held at the Sanford Consortium for Regenerative Medicine, UCSD, La Jolla, California.
MNOV: 5.98 (+0.07)
Evaluating the Technicals - Research on Hudson Technologies, Retractable Technologies, Spark Networks and MediciNova
ACCESSWIRE - Wed Dec 02, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / December 02, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hudson Technologies Inc. (NASDAQ: HDSN), Retractable Technologies Inc. (NYSE MKT: RVP), Spark Networks Inc. (NYSE MKT: LOV) and MediciNova Inc. (NASDAQ: MNOV). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HDSN: 6.19 (-0.12), MNOV: 5.98 (+0.07), RVP: 2.64 (-0.05), LOV: 1.97 (+0.09)
MediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia
GlobeNewswire - Thu Nov 19, 5:00AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it is initiating a clinical trial to investigate MN-001 (tipelukast) for the treatment of hypertriglyceridemia in NASH patients. The principal investigator is Paul J. Pockros, MD, Division Head of Gastroenterology and Hepatology at Scripps Clinic, and the trial will be primarily conducted at U.S. medical centers within SC Liver Research Consortium (SCLRC), an organization of hepatology and gastroenterology clinical research specialists which includes Scripps Clinic, University of Washington Medical Center, University of California San Diego, and Cleveland Clinic.
MNOV: 5.98 (+0.07)
MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan
GlobeNewswire - Tue Nov 10, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office of MN-221 (bedoradrine) for the treatment of irritable bowel syndrome.
MNOV: 5.98 (+0.07)
BUYINS.NET: MNOV SqueezeTrigger Price is $3.30. There is $1,268,179 That Short Sellers Still Need To Cover.
M2 - Tue Nov 10, 10:21AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring MediciNova Inc (NASDAQ:MNOV) in real time and just received an alert that MNOV is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 371900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $3.30. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
MNOV: 5.98 (+0.07)
FDA Approves a New Clinical Protocol to Evaluate the Effects of MN-166 (ibudilast) on a Biomarker of ALS; MediciNova Plans to Initiate a Clinical Trial with MGH (Massachusetts General Hospital)
GlobeNewswire - Mon Nov 09, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that the FDA (U.S. Food and Drug Administration) has approved the protocol of a new clinical trial in ALS patients, "A Single-Center, Open-Label Biomarker Study to Evaluate MN-166 (ibudilast) in Subjects with Amyotrophic Lateral Sclerosis (ALS)." This study is a collaborative effort between MediciNova, Inc. and Drs. Nazem Atassi and Haruhiko Banno, Principal Investigators at Massachusetts General Hospital's (MGH) Neurological Clinical Research Institute (NCRI) and Harvard Medical School to measure the effects of MN-166 on reducing brain microglial activation utilizing a biomarker in 15 subjects with ALS. This trial is expected to commence shortly.
MNOV: 5.98 (+0.07)
MediciNova to Initiate Clinical Trial of MN-001 (tipelukast) in IPF
GlobeNewswire - Fri Oct 09, 5:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that following completion of an agreement with Penn State (Dr. Rebecca Bascom, Principal Investigator) and IRB (Institutional Review Board) approval by Penn State Milton S. Hershey Medical Center, MediciNova will initiate a Phase 2 clinical trial of MN-001 (tipelukast) to treat moderate to severe idiopathic pulmonary fibrosis (IPF).
MNOV: 5.98 (+0.07)
MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
GlobeNewswire - Wed May 25, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that two abstracts detailing novel findings from further analysis of the completed clinical trial of MN-166 (ibudilast) in alcohol dependence have been accepted for presentation at the 39 Annual Scientific Meeting of the Research Society on Alcoholism to be held June 25-29, 2016 at the Hyatt Regency New Orleans in New Orleans, LA.
MNOV: 5.98 (+0.07)
MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada
GlobeNewswire - Wed Apr 20, 5:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, will present interim data today from MediciNova's ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the American Academy of Neurology (AAN) 68th Annual Meeting at the Vancouver Convention Centre in Vancouver, BC, Canada. The interim analysis, which was performed by an independent statistician consultant, includes a total of 25 subjects without non-invasive ventilator support who completed the 6-month double-blind treatment period with complete spirometry (respiratory function test) data.
MNOV: 5.98 (+0.07)
MediciNova, Inc. (NASDAQ: MNOV) - Analyst Coverage Initiated; Report by Broad Street
ACCESSWIRE - Mon Apr 04, 7:02AM CDT
LA JOLLA, CA / ACCESSWIRE / April 4, 2016 / MediciNova, Inc. (NASDAQ: MNOV) a biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market, recently announced that the medical journal Drug and Alcohol Dependence has published a new article regarding positive findings from a completed Phase 1b clinical trial of MN-166 (ibudilast) in methamphetamine dependence. The article, which was written by Matthew J. Worley, Keith G. Heinzerling, and colleagues at the University of California, Los Angeles (UCLA), reports that MN-166 (ibudilast) was shown to significantly reduce the subjective effects of methamphetamine in subjects diagnosed with methamphetamine dependence. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased that the detailed results of the first clinical trial evaluating MN-166 in methamphetamine-dependent subjects have been published. Based on the reported positive findings from this study, we continue to work in collaboration with researchers at UCLA on a much larger ongoing Phase 2 clinical study to evaluate MN-166 in methamphetamine-dependent subjects."
MNOV: 5.98 (+0.07)
MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
GlobeNewswire - Wed Mar 30, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the medical journal Drug and Alcohol Dependence has published a new article regarding positive findings from a completed Phase 1b clinical trial of MN-166 (ibudilast) in methamphetamine dependence. The article, which was written by Matthew J. Worley, Keith G. Heinzerling, and colleagues at the University of California, Los Angeles (UCLA), reports that MN-166 (ibudilast) was shown to significantly reduce the subjective effects of methamphetamine in subjects diagnosed with methamphetamine dependence.
MNOV: 5.98 (+0.07)
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China
GlobeNewswire - Sun Mar 27, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a notice of allowance from the Chinese Patent Office for a new patent which covers MN-001 (tipelukast).
MNOV: 5.98 (+0.07)
MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas
GlobeNewswire - Sun Feb 07, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that principal investigator Sandra Comer, Ph.D., Professor, Department of Psychiatry, Columbia University and New York State Psychiatric Institute (NYSPI), will present results of the completed Phase 2 trial which evaluated MN-166 (ibudilast) in patients with opioid dependence. Dr. Comer's presentation will be held during the symposium titled, "Glial and Neuroinflammatory Modulators for Attenuating Some Abuse-Related Effects of Drugs," at the Behavior, Biology and Chemistry Annual Meeting and Symposium.
MNOV: 5.98 (+0.07)
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis
GlobeNewswire - Wed Jan 27, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced NASH (nonalcoholic steatohepatitis) with fibrosis.
MNOV: 5.98 (+0.07)
FDA Grants Rare Pediatric Disease Designation to MediciNova's MN-166 (ibudilast) for the Treatment of Krabbe Disease
GlobeNewswire - Mon Jan 18, 5:16PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to MN-166 (ibudilast) for treatment of Type 1 - Early Infantile Krabbe disease. Under the FDA's rare pediatric disease priority review voucher program, the sponsor may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug application. The FDA has previously granted orphan drug designation to MN-166 (ibudilast) for treatment of Krabbe disease.
MNOV: 5.98 (+0.07)
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in Europe
GlobeNewswire - Wed Jan 13, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced receipt from the European Patent Office of a notice of intent to allow patent for MN-029 (denibulin) di-hydrochloride.
MNOV: 5.98 (+0.07)
FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis
GlobeNewswire - Wed Dec 16, 5:00AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for MN-166 (ibudilast) for the treatment of patients with amyotrophic lateral sclerosis (ALS). Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA's Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.
MNOV: 5.98 (+0.07)
MediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in China
GlobeNewswire - Mon Dec 14, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a notice of allowance for a new patent from the Chinese Patent Office which covers MN-029 (denibulin) di-hydrochloride.
MNOV: 5.98 (+0.07)
MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL
GlobeNewswire - Sun Dec 13, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, today presented interim data from MediciNova's ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 26th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) in Orlando, FL. The interim analysis includes a total of 36 subjects, and 33 of those subjects completed 6 months of treatment on study drug (MN-166 or placebo in a 2:1 ratio).
MNOV: 5.98 (+0.07)
MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
GlobeNewswire - Wed Dec 09, 4:30PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Daniel Roche today presented results based on the completed study which evaluated the safety and efficacy of MN-166 (ibudilast) in alcohol use disorder (Dr. Lara Ray, UCLA, Principal Investigator) at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting.
MNOV: 5.98 (+0.07)
MediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th Annual California ALS Pac10 and Research Network Meeting at UCSD, La Jolla, Californiaã??
GlobeNewswire - Sun Dec 06, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that Dr. Yuichi Iwaki, President and CEO, has accepted an invitation to make a presentation regarding the ongoing clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 6th Annual California ALS Pac10 and Research Network Meeting which will be held at the Sanford Consortium for Regenerative Medicine, UCSD, La Jolla, California.
MNOV: 5.98 (+0.07)
Evaluating the Technicals - Research on Hudson Technologies, Retractable Technologies, Spark Networks and MediciNova
ACCESSWIRE - Wed Dec 02, 6:45AM CST
NEW YORK, NY / ACCESSWIRE / December 02, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Hudson Technologies Inc. (NASDAQ: HDSN), Retractable Technologies Inc. (NYSE MKT: RVP), Spark Networks Inc. (NYSE MKT: LOV) and MediciNova Inc. (NASDAQ: MNOV). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HDSN: 6.19 (-0.12), MNOV: 5.98 (+0.07), RVP: 2.64 (-0.05), LOV: 1.97 (+0.09)
MediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia
GlobeNewswire - Thu Nov 19, 5:00AM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it is initiating a clinical trial to investigate MN-001 (tipelukast) for the treatment of hypertriglyceridemia in NASH patients. The principal investigator is Paul J. Pockros, MD, Division Head of Gastroenterology and Hepatology at Scripps Clinic, and the trial will be primarily conducted at U.S. medical centers within SC Liver Research Consortium (SCLRC), an organization of hepatology and gastroenterology clinical research specialists which includes Scripps Clinic, University of Washington Medical Center, University of California San Diego, and Cleveland Clinic.
MNOV: 5.98 (+0.07)
MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan
GlobeNewswire - Tue Nov 10, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office of MN-221 (bedoradrine) for the treatment of irritable bowel syndrome.
MNOV: 5.98 (+0.07)
BUYINS.NET: MNOV SqueezeTrigger Price is $3.30. There is $1,268,179 That Short Sellers Still Need To Cover.
M2 - Tue Nov 10, 10:21AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring MediciNova Inc (NASDAQ:MNOV) in real time and just received an alert that MNOV is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 371900 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $3.30. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
MNOV: 5.98 (+0.07)
FDA Approves a New Clinical Protocol to Evaluate the Effects of MN-166 (ibudilast) on a Biomarker of ALS; MediciNova Plans to Initiate a Clinical Trial with MGH (Massachusetts General Hospital)
GlobeNewswire - Mon Nov 09, 5:00PM CST
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that the FDA (U.S. Food and Drug Administration) has approved the protocol of a new clinical trial in ALS patients, "A Single-Center, Open-Label Biomarker Study to Evaluate MN-166 (ibudilast) in Subjects with Amyotrophic Lateral Sclerosis (ALS)." This study is a collaborative effort between MediciNova, Inc. and Drs. Nazem Atassi and Haruhiko Banno, Principal Investigators at Massachusetts General Hospital's (MGH) Neurological Clinical Research Institute (NCRI) and Harvard Medical School to measure the effects of MN-166 on reducing brain microglial activation utilizing a biomarker in 15 subjects with ALS. This trial is expected to commence shortly.
MNOV: 5.98 (+0.07)
MediciNova to Initiate Clinical Trial of MN-001 (tipelukast) in IPF
GlobeNewswire - Fri Oct 09, 5:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that following completion of an agreement with Penn State (Dr. Rebecca Bascom, Principal Investigator) and IRB (Institutional Review Board) approval by Penn State Milton S. Hershey Medical Center, MediciNova will initiate a Phase 2 clinical trial of MN-001 (tipelukast) to treat moderate to severe idiopathic pulmonary fibrosis (IPF).
MNOV: 5.98 (+0.07)
